Tag: Synaffix
Dutch Biotech Signs License Agreement with Chinese ADC Developer
The Dutch biotech company Synaffix has signed a license agreement with the Chinese ADC developer Shanghai Miracogen. The agreement is estimated to be worth...
First Patient Dosed in Phase I Trial with Pyrrolobenzodiazepine-based Antibody-drug conjugate...
The development of proprietary, pyrrolobenzodiazepine-based, antibody-drug conjugates or ADCs targeting AXL, has entered a news phase with the dosing of the first patient in...
Mersana Therapeutics Focuses its Resources on Advancing XMT-1536, its First-in-Class ADC...
Mersana Therapeutics, a clinical-stage biopharmaceutical company developing a pipeline of antibody-drug conjugates or ADCs designed to target cancers in areas of high unmet need,...
New ADC Payload Platform – Synaffix Launches toxSYN™
The Netherlands-based biotech company Synaffix, which has developed a proprietary site-specific conjugation platform technology to enable differentiated antibody-drug conjugates or ADCs, launched of a...
Synaffix Secures End-to-end Patent Protection for GlycoConnect Technology
The Netherlands-based Synaffix, a biotechnology company that has developed a proprietary site-specific platform technology to enable differentiated antibody-drug conjugates (ADCs), has received a key...
Synaffix ADCs Significantly Expands the Therapeutic Index vs Cysteine-Engineered ADCs
Netherlands-bases biotechnology company Synaffix BV, which exclusively focuses on the development of novel antibody-drug conjugate (ADC) technology, confirmed that a new set of head-to-head...
New Key Patent Covers Synaffix’s Glycan-Conjugated ADC Development Process
Synaffix, a Netherlands-based biotechnology company exclusively focused on the continued advancement of best-in-class ADC technology platforms has received a new key patent for their...
Synaffix and ADC Therapeutics Sign Agreement for GlycoConnect™ and HydraSpace™ Technologies
Netherlands-based biotechnology company Synaffix has entered into a Commercial License Agreement with ADC Therapeutics for its proprietary site-specific antibody-drug conjugate technologies. The company is exclusively focused...
Preclinical Studies Show Significant Improved Therapeutic Index
Synaffix, a Netherlands-based biotechnology company exclusively focusing on the continued advancement of best-in-class and industry leading antibody-drug conjugate (ADC) technology platforms, has competed a new set...
Synaffix’s New High Potency Lab now Fully Operational to Support Growing...
Late last week, Synaffix, a Dutch biotechnology company backed by a top tier, life science-focused, investor syndicate and the strategic corporate venture capital fund of...
